Company Overview
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.35.
Recent Developments
- Dec 2025 Revenue of $2.85M (+20.4% YoY); net profit $-143.44M.
- Trailing 12 Months Year-on-year growth — revenue -17.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.51% |
| 1 Year: | -17.50% |
Stock Price Performance
| 1 Year: | -85.24% |
| 6 Months: | -70.54% |
| 3 Months: | -57.19% |
| 1 Month: | -47.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)20.03 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 91.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 20 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UPB Upstream Bio, Inc. R2KR3KPHARMA | 2.74 | -0.95 | $150.07M | 0.00% | -47.12% | -46.05% | 9.51% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 621.00K | 640.00K | 510.00K | 607.00K | 566.00K | 937.00K | 683.00K | 1.03M |
| Operating Income | - | - | -9.39M | -15.01M | -17.54M | -18.89M | -32.01M | -44.35M | -37.83M | -43.62M |
| Net Income | -3.06M | -2.54M | -3.10M | -10.89M | -14.68M | -15.99M | -27.27M | -39.97M | -33.75M | -40.59M |
| Diluted EPS | - | - | -2.11 | -4.68 | -6.50 | -6.96 | -0.51 | -0.74 | -0.63 | -0.75 |
| R&D Expense | - | - | 7.79M | 11.69M | 14.07M | 15.43M | 25.80M | 37.87M | 32.98M | 36.56M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 2.38M | 2.37M | 2.85M |
| Operating Income | -40.11M | -77.76M | -160.36M |
| Net Income | -20.54M | -62.81M | -143.44M |
| Diluted EPS | -12.95 | -5.58 | -2.66 |
| R&D Expense | 31.80M | 62.97M | 136.81M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 117.20M | 481.72M | 353.77M |
| Total Equity | -106.16M | -123.13M | 469.85M | 339.77M |
| Cash & Equivalents | - | 25.83M | 325.89M | 101.58M |
| Total Liabilities | - | 9.39M | 11.87M | 14.00M |
| Current Liabilities | - | 6.51M | 10.74M | 13.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -37.93M | -59.17M | -133.28M |
| Investing Cash Flow | -82.84M | -59.48M | -93.48M |
| Financing Cash Flow | 129.55M | 418.91M | 2.44M |
| Capital Expenditure | -144.00K | -511.00K | -165.00K |
| Free Cash Flow | -38.07M | -59.68M | -133.44M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -1,685.5% | -3,281.2% | -5,618.8% |
| Net Margin % | -862.9% | -2,650.0% | -5,026.0% |
| ROE % | 16.7% | -13.4% | -42.2% |
| ROCE % | -36.2% | -16.5% | -47.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.90% | 8.16M | $38.37M |
| 2 | Orbimed Advisors LLC. | 10.40% | 5.69M | $26.76M |
| 3 | NORGES BANK | 6.88% | 3.77M | $17.71M |
| 4 | Blackrock Inc. | 6.85% | 3.75M | $17.64M |
| 5 | Decheng Capital LLC | 4.98% | 2.72M | $12.81M |
| 6 | Enavate Sciences Gp, LLC | 4.49% | 2.46M | $11.56M |
| 7 | Vanguard Capital Management LLC | 3.43% | 1.88M | $8.82M |
| 8 | Millennium Management Llc | 2.09% | 1.14M | $5.38M |
| 9 | Shaw D.E. & Co., Inc. | 1.89% | 1.04M | $4.87M |
| 10 | JPMORGAN CHASE & CO | 1.85% | 1.01M | $4.76M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UPB
UPB Nov 2026 2.500 put (UPB261120P00002500) stock historical prices and data - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE9vcDZvQi1ocEZ6bjQ1a1FsLTh2SkZRRWhGbThmMWRaVUlndnc2QnB3MXZKcXduWnowaWdqb0NNYmxfSkRRNk1kSHFYLWJtdGMxcXk3YWJvekloRWEtZ3VTSDlYWlhYOHBLejlIMkp0VQ?oc=5" target="_blank">UPB Nov 2026 2.50…
UPB Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFB2LUlVR3Byb3lSZG5ubHB1VFZ1ZjJaUW5ocllPTDRsNERwc0J0dU9kSHREdFQwV0FjM292VGJPNmFaR21IbUhVSG9hREY1a2JBd3pPZEFFS3Nvd1huZ1RObktKd2RvNVVEZ3NsOFRSSDZzVVJwWkoxRQ?oc=5" target="_blank">UPB F…
Why Did UPB Stock Plunge 40% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSzA5R0d3U2QyOTh2ckpOUFRCUk9oWENLWDdvRDNMODZMYnpuQmlSbmNSQURRTTQtV2k2Y2xhcGlIMTV5V3ZEUUZEWkZ4VUd6cDV3MUI4Q2NrWjFIX1hZY1lHbWViS2g5UjdEUW4tZHdZaTJtUXY1MHhyRm9RUEdjR0pQTVh3WDRPMllNRm…
H.C. Wainwright Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $36 - Moomoo
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPSDNlSkxvdUJMdzZ6T1d2SjU1c2dvdURQZUlEQlVvRDMzbXVvWjVOY3dXSDVWajQ4SmU3bFFnUDVKNXdFVlUwLW1BY1RIM09iQllGQ1ZlQzU5di10Z3c1amtEOXlJUGd1SXJ2dklOcUZlNTQ4XzhfbDhhTWYydkdiMzdMQk0tSlc0dGtiX3…
UPB Nov 2026 2.500 call (UPB261120C00002500) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE9fd2hMczZvZkVOaFFMaExXZGI0TzRrc3dlTVRwZ3BHZ21wLV95OWxvRGNoRlB1cTJXeGRCTzFLUVBYMlRWMXQ2YXpDN0dFMUpqUVBzUUJZY00tRUZHUWkzSkdLRTY?oc=5" target="_blank">UPB Nov 2026 2.500 call (UPB2611…
$UPB stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQS2lGZ2ltNUl5UzhXMlcwc3JOczd4RDk1S3FoYlR4eVItY01mSnZCRzlra3VZaVBoSTVFTlhEMlVkSENjSWhYbm1pdmVRUVA2SDJZMGMxbWhoSTlwRmtpUmVCSTRBMU5fMjR2QjJMdktpSWIxTG40ZlN0NWJ3YkdwcHNlY2gwRzVpczFBem…
UPB — Frequently Asked Questions
What is the current share price of Upstream Bio, Inc. (UPB)?
As of 2026-10-23 16:27 PDT, Upstream Bio, Inc. (UPB) trades at $2.74 on NasdaqGS. Its 52-week range is $2.74 to $32.60.
What is the market capitalisation of UPB?
Upstream Bio, Inc. (UPB) has a market capitalisation of $150.07M on NasdaqGS.
What is the P/E ratio of UPB?
UPB trades at a trailing price-to-earnings (P/E) ratio of -0.95. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.08.
What is the return on equity (ROE) of UPB?
UPB has a return on equity (ROE) of -46.05%. Its return on capital employed (ROCE) is -47.12%.
Is UPB a good stock to buy?
This page provides a data-driven analysis of Upstream Bio, Inc. (UPB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.